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Abstract
Background: Chemotherapy with or without surgery is the first-line treatment for stage III/IV gastric cancer, while
surgery is the first-line treatment for stage I/II gastric cancer. Accordingly, it is important to distinguish between
stage III/IV and stage I/II gastric cancer, but clinical staging is less accurate than pathological staging. This study was
performed to develop a clinical score that could distinguish stage III/IV gastric cancer from stage I/II gastric cancer.
Methods: We reviewed 2722 patients who underwent gastrectomy at our hospital from January 1996 to December
2015. As pretreatment factors potentially related to tumor stage, we assessed age, sex, tumor markers, tumor
diameter, tumor location, tumor histology, and macroscopic type. Factors showing significance on multivariate
analysis were used to develop the Clinical Stage Prediction score (CSP score), and a cutoff value for the score was
determined by receiver operating characteristics analysis.
Results: According to multivariate analysis, clinical factors associated with stage III/IV disease were elevation of the
carcinoembryonic antigen level, tumor diameter ≥ 60 mm, circumferential gastric involvement, esophageal
infiltration, mucinous adenocarcinoma, and macroscopic types 2–4.
The CSP score was obtained by weighting these factors according to the non-standardized β-coefficient. Receiver
operating characteristics analysis indicated that the optimum cutoff value of the CSP score was 17 points. Among
1042 patients with a CSP score ≥ 17 points, 820 patients (78.7%) had stage III/IV gastric cancer. Conversely, among
1680 patients with a CSP score < 17 points, 1547 patients (92.1%) had stage I/II gastric cancer. When discrimination
of stage III/IV gastric cancer from stage I/II gastric cancer by the CSP score was assessed, the sensitivity was 78.7%,
specificity was 92.1%, positive predictive value was 86.0%, and negative predictive value was 87.5%.
Conclusions: The CSP score can be helpful for differentiating stage III/IV gastric cancer from stage I/II gastric cancer
based on pretreatment clinical factors.
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Background
In patients with stage I/II gastric cancer, a good outcome
can be achieved by endoscopic resection or standard
surgical treatment. On the other hand, although most
patients with stage III/IV gastric cancer undergo resec-
tion of the primary tumor, the overall survival rate is
only 14.9–67.1% [1, 2]. Gastrectomy with postoperative
adjuvant chemotherapy is currently the standard treat-
ment for stage III gastric cancer, but preoperative neoad-
juvant chemotherapy using more potent anticancer
agents shows promise of improving the outcome. While
chemotherapy is the primary treatment for stage IV gas-
tric cancer, it is expected that also performing surgery
may prolong survival. If chemotherapy is accepted as
first-line treatment for stage III/IV gastric cancer, while
surgery is first-line treatment for stage I/II gastric cancer,
it is important to make a differential diagnosis between
stage III/IV and stage I/II disease. However, conventional
clinical diagnosis is less accurate than pathological
diagnosis. Therefore, we performed a retrospective
analysis of factors used to make a clinical diagnosis be-
fore treatment and developed a Clinical Stage Prediction
score (CSP score). Then, we investigated whether stage
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: ktaniguchi@twmu.ac.jp
Department of Surgery, Institute of Gastroenterology, Tokyo Women’s
Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
Taniguchi et al. World Journal of Surgical Oncology           (2019) 17:47 
https://doi.org/10.1186/s12957-019-1589-5
III/IV gastric cancer could be differentiated from stage I/
II gastric cancer by using the CSP score.
Methods
Between 1996 and 2015, a total of 2722 patients with
primary gastric cancer, excluding patients with cancer of
the remnant stomach, underwent surgery at the Tokyo
Women’s Medical University Hospital (Tokyo, Japan).
Our institutional review board waived the need for in-
formed consent because this was a retrospective study.
TNM categories were determined according to the Japa-
nese classification of gastric carcinoma [3] (Table 1),
which is widely used. In this classification, the depth of
tumor invasion is recorded as the T category, lymph
node metastasis is recorded as the N category, and the
presence/absence and sites of distant metastasis are
recoded as the M category.
Various pretreatment factors were investigated as po-
tential predictors of tumor stage, including the age, sex,
tumor markers (serum carcinoembryonic antigen (CEA)
(≤ 5.0 ng/ml vs. ≥ 5.1 ng/ml) and serum cancer antigen
19-9 (CA19-9) (≤ 37 U/ml vs. ≥ 38 U/ml)), and tumor
diameter (≤ 59mm vs. ≥ 60 mm). To investigate the pre-
dictive value of tumor location and extent, the stomach
was divided into thirds (upper third, middle third, and
lower third) and the gastric circumference was divided
into four equal parts for assessment of circumferential
involvement (lesser curvature, greater curvature, anterior
wall, and posterior wall; a circumferential category was
also added). Extension of the tumor into the esophagus
or duodenum was also assessed. Finally, the histological
type and the macroscopic type (Types 0–4) were investi-
gated. Macroscopic and histological types were deter-
mined according to the Japanese classification of gastric
carcinoma [3].
Statistical analysis
We initially investigated the association between pre-
treatment factors and tumor stage (I/II vs. III/IV) by
univariate logistic regression analysis. Then, we entered
the candidate factors identified by univariate analysis as
explanatory variables for multivariate logistic regression
analysis. Subsequently, the factors that predicted tumor
stage were weighted according to the relative magnitude
of the β-coefficient in logistic regression analysis to de-
velop the CSP score.
Receiver operating characteristics (ROC) analysis was
performed, and the cut-off value of the CSP score was cal-
culated from the ROC curve by determining the Youden
index. The accuracy of the CSP score for staging gastric
cancer (I/II vs. III/IV) was evaluated in our patient cohort
by the chi-square test. All analyses were performed with
JMP software ver. 12 (SAS Institute, Cary, NC).
Results
Univariate analysis
Table 2 shows the associations between tumor stage (I/II
vs. III/IV) and pretreatment factors according to univari-
ate analysis.
A tumor diameter ≥ 60 mm and higher levels of both
tumor markers (CEA and CA19-9) were significantly as-
sociated with stage III/IV disease.
Regarding the influence of tumor extent and location,
stage III/IV disease was significantly associated with tu-
mors located on the anterior wall or posterior wall of
the stomach, circumferential tumors, tumors in the
upper third or middle third of the stomach, and tumors
invading the esophagus or duodenum. With regard to
histology, well-differentiated adenocarcinoma and signet
ring cell carcinoma were associated with stage I/II dis-
ease, while mucinous carcinoma was related to stage III/
IV disease. Finally, macroscopic tumor types 2, 3, and 4
were significantly associated with stage III/IV disease.
Multivariate analysis
We employed 21 factors that were significant accord-
ing to univariate analysis as covariates for multivariate
logistic regression analysis. Factors confirmed to be
significant for discriminating tumor stage (I/II vs. III/
Table 1 Patient characteristics
Age 63.7 ± 11.8
Sex
M 1849
F 873
T
M 647
SM 581
MP 283
SS 173
SE 858
SI 180
N
N0 1498
N1 580
N2 417
N3 227
M
M0 100
M0 2622
P1 233
P0 2485
TNM categories were determined according to the Japanese classification of
gastric carcinoma [3]
Taniguchi et al. World Journal of Surgical Oncology           (2019) 17:47 Page 2 of 6
IV) by multivariate analysis were tumor markers
(CEA and CA19-9), tumor diameter ≥ 60 mm, macro-
scopic type (type 0, type 2, type 3, and type 4), mu-
cinous histology, and infiltration of the esophagus.
However, the other 13 factors were not independent
predictors (Table 2).
Establishment of the Clinical Stage Prediction score
The CSP score was devised by assigning scores for the
factors identified by multivariate analysis, with weighting
according to the relative magnitude of the non-standard-
ized β-coefficient. One point was assigned for mucinous
histology, while two points each were assigned for
Table 2 Analysis of preoperative factors and tumor stage
Stage I/II Percent Stage III/IV Percent Total Univariate analysis Multivariate analysis
n = 1769 n = 953 P value P value
Age 62.0 ± 11.4 63.7 ± 11.8 0.0013 0.3454
Sex F354/M704 F312/M630 F666/M1334 0.6327
Tumor markers
CA19-9 139 33.74 273 66.26 412 0.0002 0.3063
CEA 167 41.34 237 58.66 404 < 0.0001 0.0031
Tumor diameter
≤ 59 1441 86.4 225 13.6 1666
≥ 60 328 31.06 728 68.94 1056 < 0.0001 < 0.0001
Location/extent
Anterior wall 283 77.11 84 2.89 3667 < 0.0001 0.5661
Posterior wall 427 77.5 124 2.5 551 < 0.0001 0.1243
Lesser curvature 705 66.89 349 33.11 1054 0.0987
Greater curvature 304 68.93 137 31.07 441 0.0578
Circumferential 50 16.18 259 83.82 309 < 0.0001 0.0205
Upper third 307 56 241 433.98 548 < 0.0001 0.7119
Middle third 855 69.85 369 30.15 1224 < 0.0001 0.3593
Lower third 607 63.89 343 36.11 950 0.3809
Esophagus 39 23.64 126 76.36 165 < 0.0001 0.0611
duodenum 43 25 129 75 172 < 0.0001 0.2652
Histology
TB1 449 82.39 96 17.61 545 < 0.0001 0.8469
TB2 436 63.01 256 36.99 692 0.2053
por1 75 53.96 64 46.04 139 0.0061 0.7613
por2 471 52.63 424 47.37 895 < 0.0001 0.221
SIG 241 93.05 18 6.95 259 < 0.0001 0.133
PAP 56 64.37 31 35.63 87 0.9017
MUC 29 34.12 56 67.88 85 < 0.0001 0.0225
ASQ 2 33.33 4 66.67 6 0.1924
Macroscopic type
Type 0 1278 98.38 21 1.62 1299 < 0.0001 0.0003
Type 1 53 62.35 32 37.65 85 0.6443
Type 2 146 44.11 185 55.89 331 < 0.0001 < 0.0001
Type 3 241 32.01 512 67.99 753 < 0.0001 < 0.0001
Type 4 41 17.83 189 82.17 230 < 0.0001 0.0032
When 21 factors that were significant by univariate analysis were used as covariates for multivariate logistic regression analysis, the significant factors for
discriminating tumor stage (I/II vs. III/IV) were tumor markers (CEA and CA19-9), tumor diameter ≥ 60 mm, macroscopic type (type 0, type 2, type 3, and type 4),
mucinous histology, and infiltration of the esophagus. Abbreviations: TB1 well-differentiated adenocarcinoma, TB2 moderately differentiated adenocarcinoma, por1
solid poorly differentiated adenocarcinoma, por2 non-solid poorly differentiated adenocarcinoma, SIG signet ring cell carcinoma, PAP papillary adenocarcinoma,
MUC mucinous adenocarcinoma, ASQ adenosquamous carcinoma
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elevation of CEA, circumferential involvement, and infil-
tration of the esophagus. Eight points were given for a
tumor diameter ≥ 60mm. Macroscopic types 2 and 4 re-
ceived 10 points, while macroscopic type 3 was assigned
16 points because the relative β-coefficient was approxi-
mately twice that of the other types (Table 3).
Then ROC analysis was performed to identify the best
cut-off value for the CSP score, which was set at 17
points based on the Youden index (Fig. 1). The accuracy
of a CSP score > 17 points for identifying stage III/IV
disease was 78.7% (95% confidence interval [CI] 49.4–
65.3%), while the accuracy of a score < 17 points for
identifying stage I/II disease was 92.1% (95% CI 83.7–
88.8%) When discrimination of stage III/IV gastric can-
cer from stage I/II gastric cancer by the CSP score was
investigated, its sensitivity was 78.7%, specificity was
92.1%, positive predictive value was 86.0%, and negative
predictive value was 87.5% (Table 4).
Discussion
We devised a new staging score for gastric cancer (the
CSP score) by analysis of pretreatment factors in 2722
patients, and we demonstrated that this score could ef-
fectively discriminate between stage I/II disease and
stage III/IV disease before initiation of treatment. It has
been reported that preoperative chemotherapy may im-
prove outcomes for stage III/IV disease, suggesting that
an accurate method of predicting the stage before start-
ing treatment could be useful. Numerous prognostic fac-
tors for gastric cancer have been reported, including the
depth of tumor invasion [4], site of lymph node metasta-
sis [4], number of metastatic lymph nodes [5–7] lymph
node metastasis ratio [7–9], distant metastasis [4],
results of peritoneal lavage cytodiagnosis [10, 11], tumor
diameter [12], macroscopic type [13, 14], tumor location
[15, 16], age [17, 18], sex [17], lymphatic invasion [19],
venous invasion [20], histologic type [21], macroscopic
serosal invasion [22], tumor markers (CEA and CA19-9)
[23, 24], and extent of lymphadenectomy [24–26]. Most
of these factors can be assessed before initiation of treat-
ment, apart from those related to lymph nodes, lymph-
atic invasion, and venous invasion.
In the present study, both the tumor size and macro-
scopic type were confirmed to be useful for identifying
advanced disease. Mucinous carcinoma was also a sig-
nificant factor on multivariate analysis, which is reason-
able since 90% of mucinous tumors are advanced
because early cancers release most of their mucin into
the gastric lumen [27].
Various modalities are employed for diagnosis and sta-
ging of gastric cancer, with each method being influenced
by inherent characteristics, observation conditions, instru-
ment performance, and differences between institutions.
Therefore, clinical staging of gastric cancer has a relatively
low accuracy (60–70%) compared with pathological sta-
ging [28–33]. Also, endoscopic staging is often based on
clinical experience because of the lack of objective criteria
for assessing the depth of invasion. While endoscopic
ultrasonography (EUS) is useful, it is difficult to determine
the depth of ulcerated lesions and the accuracy is no bet-
ter than that of standard endoscopic diagnosis [29]. Ac-
cordingly, we investigated preoperative factors related to
tumor stage and we devised the CSP score by weighting
each factor to obtain a useful predictor of gastric cancer
stage. The depth of invasion is assessed preoperatively by
endoscopic observation, EUS, and abdominal ultrasound.
Table 3 Scores of the factors for predicting the stage of gastric cancer
Multivariate analysis P value β-coefficient Weighted score
Tumor marker
CEA 0.0031 0.08 2
Tumor diameter
≥ 60 < 0.0001 0.24 8
Location/extent
Circumferential 0.0205 0.09 2
Esophagus 0.0441 0.07 2
Histology
Mucinous 0.0284 0.04 1
Macroscopic type
Type 0 0.0003 − 0.274 − 7
Type 2 < 0.0001 0.3 10
Type 3 < 0.0001 0.48 16
Type 4 0.00042 0.3 10
The CSP score was devised by assigning scores for the factors identified by multivariate analysis, with weighting according to the relative magnitude of the
non-standardized β-coefficient
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It has been reported that NBI observation achieves 92%
accuracy for determining the depth of invasion of early
gastric cancer, but this decreases to 57–86% with white
light observation and is around 74% for EUS [29].
EUS, CT, positron emission tomography, and ab-
dominal ultrasound can all be used to assess lymph
node metastasis, but the reported accuracy varies
widely from 50 to 92% [30–32]. Accuracy of CT is
comparatively high among these modalities, with
lymph nodes > 10 mm in diameter being detectable
and visible nodes likely to be metastatic [33]. How-
ever, many metastatic nodes are not enlarged, and it
is impossible to predict the presence/absence of me-
tastasis from size alone. Also, tumor progression is
judged by the number of nodal metastases, but it is
difficult to separate N1 (1–2 nodes involved) from
N2 (3–5 nodes involved). On the other hand, im-
aging is useful for assessing the tumor diameter and
distant metastasis, except for remote lymph node
metastasis or micrometastases, while laparoscopic
examination can be performed to identify peritoneal
metastases [33].
Various scoring systems for gastric cancer have been
reported that predict the prognosis, complications, or
risks for elderly patients. A depth prediction score that
separates M-SM1 disease from SM2 disease based on
endoscopic findings such as tumor location, macroscopic
type, and tumor size has also been reported. However,
there have been few reports about diagnostic scores or
methods that can judge the applicability of endoscopic
treatment for early gastric cancer [34].
A risk score system has also been reported for pre-
operative prediction of the TNM stage of gastric cancer
based on four factors: serum albumin, tumor size, and
the T and N categories determined by helical computed
tomography. When that score was investigated in 108
curatively resected patients, it showed poor versatility
due to the large influence of the computed tomography
findings [35].
While staging of gastric cancer is based on T, N, and
M factors, the pretreatment factors in the CSP score are
also associated with the prognosis or stage, and T, N,
and M factors were specifically excluded from the CSP
score to increase its objectivity and versatility.
Moreover, there have been no previous reports of a
staging score that can be used to decide whether a pa-
tient should receive preoperative chemotherapy, which
is the function of the CPS score developed in this study.
While we found that the CPS score was effective for
discriminating between low- and high-stage disease, its
sensitivity was somewhat low (78.9%). It is possible that
the sensitivity of the CSP score could be improved by
adding factors related to the nutritional status (albumin
or prealbumin) and tumor markers (CA125 or AFP).
Fig. 1 ROC curve of the CSP score. ROC analysis was performed to identify the optimum cut-off value for the CSP score, which was 17 points
based on the Youden index
Table 4 Tumor stage and the CSP score
CSP score Stage I/II Stage III/IV Total
> 17 points 222 pts 820 pts (78.7%) 1042 pts
≤ 17 points 1547 pts (92.1%) 133 pts 1680 pts
Total 1769 pts 953 pts 2722 pts
Sensitivity 78.7%
Specificity 92.1%
Positive predictive value 86%
Negative predictive value 87.5%
The accuracy of a CSP score > 17 points for identifying stage III/IV disease was
78.7% (95% confidence interval [CI] 49.4–65.3%), while the accuracy of a score
< 17 points for identifying stage I/II disease was 92.1% (95% CI 83.7–88.8%)
For discriminating stage III/IV gastric cancer from stage I/II gastric cancer, the
sensitivity was 78.7%, specificity was 92.1%, positive predictive value was
86.0%, and negative predictive value was 87.5%. Abbreviation: pts patients
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Conclusion
The CSP score that we devised employs weighted pre-
treatment factors to differentiate stage I/II gastric cancer
from stage III/IV gastric cancer. This allows discussion
of all possibilities and evaluation of the optimum treat-
ment strategy before surgery is performed.
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